Advanced Soft Tissue Sarcoma Treatment Considerations

Leiomyosarcoma

Classified as uterine or nonuterine

Leiomyosarcoma classified as uterine or nonuterine accounts for approximately 24% of soft tissue sarcomas in adults

of soft tissue sarcomas in adults.*1

Liposarcoma

Liposarcoma accounts for approximately 12% of soft tissue sarcomas in adults Subtypes2
Myxoid/Round Cell
Well-differentiated
Pleomorphic
Dedifferentiated

of soft tissue sarcomas in adults.*1

*Percentages based on incidence data from 1978-2001 collected in the 9 Surveillance, Epidemiology and End Results (SEER) program areas. Cases of soft tissue sarcoma were categorized into major histologic types and subtypes, according to criteria specified in the 2002 World Health Organization Classification of Tumours and the recommendations of an expert pathologist. Additional cases that met the morphologic criteria of soft tissue sarcoma regardless of primary site, except bones and joints, were added for a total of 26,758 cases used in the analysis.

Treating patients with unresectable or metastatic leiomyosarcoma or liposarcoma

Treatment considerations should include tumor characteristics3:

Treatment

  • Chemosensitivity of histological subtype3
  • Natural history3
  • Tumor burden3
  • Tumor stage4
  • Tumor grade4

Clinical characteristics3:

Clinical

  • Patient’s general condition and level of symptoms3
  • Comorbidities3
  • Previous treatments3
  • Patient goals3

Delaying disease progression is one measure of treatment success in advanced soft tissue sarcoma5

Progression-free survival (PFS) is the time from randomization to objective tumor progression or death.5

PFS

  • PFS allows new treatments to be evaluated in smaller studies and over shorter periods of time, and results are not confounded by subsequent lines of therapy.5

Consider YONDELIS®

YONDELIS® is the only treatment recently approved specifically for unresectable or metastatic liposarcoma or leiomyosarcoma after an anthracycline-containing regimen.

References:

  1. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CDM, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922-2930.
  2. Henze J, Bauer S. Liposarcomas. Hematol Oncol Clin N Am. 2013;27(5):939-955.
  3. Blay J-Y, Sleijfer S, Schöffski P, et al. International expert opinion on patient-tailored management of soft tissue sarcomas. Eur J Cancer. 2014;50(4):679-689.
  4. Grimer R, Judson I, Peake D, Seddon D. Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010;2010:506182. doi:10.1155/2010/506182.
  5. Chmielowski B, Federman N, Tap WD. Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas. Expert Rev Anticancer Ther. 2012;12(9):1217–1228.